WINNIPEG, MANITOBA--(MARKET WIRE)--Sep 18, 2007 -- DiaMedica Inc. (CDNX:DMA.V - News), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to announce positive pre-clinical data for DM-83, its second clinical drug candidate.
